|
Kent Iverson has over 18 years experience in the manufacturing and development of biopharmaceutical products. After completing a Bachelor's degree in Fermentation Science at UC Davis, Kent began his career in biotechnology with Genentech. Kent worked within the manufacturing function through Genentech's first 2 product approvals (Protropin™ and Activase™) and was involved with the commissioning of Genentech's first large scale mammalian cell culture facility. Kent then worked with Immunex for 9 years; during his tenure, Immunex brought 3 biopharmaceutical facilities into operation and had its first drug approval (Leukine™). Kent also led the operational project team responsible for production and supply of Enbrel™. Kent led the manufacturing and process development function at Coulter Pharmaceutical from 1997 through the acquisition of Coulter Pharmaceutical by Corixa. Kent led the process and supply chain development for Bexxar, a radiolabeled monoclonal antibody approved by FDA in 2003 for the treatment of Non-Hodgkin's Lymphoma. After the Coulter-Corixa merger, Kent continued on with Corixa as the Vice President of process development. Kent had oversight for process and formulation development, and management of outsourced production and supply of recombinant proteins, antibodies, small molecules and conjugates. Since October of 2001, Kent has been an independent biopharmaceutical manufacturing and development consultant serving North American and European clients. |